Latest period
−$41.95M
YoY change
-31.6%
5Y CAGR
—
Peak year (2021)
$118.43M
Latest annual
−$38.33M
Free Cash Flow history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: −$38.33M
Free Cash Flow growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -31.6%
Free Cash Flow history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | −$38.33M | -31.6% | +$17.69M | ||
| 2024 | −$56.03M | +22.0% | −$10.11M | ||
| 2023 | −$45.92M | -18.9% | +$10.73M | ||
| 2022 | −$56.65M | -147.8% | −$175.07M | ||
| 2021 | $118.43M | -327.9% | +$170.40M | ||
| 2020 | −$51.97M | +1.2% | −$639.93K | ||
| 2019 | −$51.33M | +11.8% | −$5.42M | ||
| 2018 | −$45.91M | +45.7% | −$14.39M | ||
| 2017 | −$31.52M | +75.2% | −$13.53M | ||
| 2016 | −$17.99M | +224.6% | −$12.45M | ||
| 2015 | −$5.54M | +2006.6% | −$5.28M | ||
| 2014 | −$263.06K | — | — |
- 2025−$38.33M-31.6%
- 2024−$56.03M+22.0%
- 2023−$45.92M-18.9%
- 2022−$56.65M-147.8%
- 2021$118.43M-327.9%
- 2020−$51.97M+1.2%
- 2019−$51.33M+11.8%
- 2018−$45.91M+45.7%
- 2017−$31.52M+75.2%
- 2016−$17.99M+224.6%
- 2015−$5.54M+2006.6%
- 2014−$263.06K—
Free Cash Flow values are taken from Ovid Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Ovid Therapeutics (OVID)
Free Cash Flow for Ovid Therapeutics (OVID): headline value −$41.95M · YoY -31.6%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual free cash flow for Ovid Therapeutics (OVID) came in at −$38.33M – plunged 31.6% year-over-year.
Ovid Therapeutics free cash flow plunged from $118.43M in 2021 to −$38.33M in 2025, a 132.4% drawdown.
The record annual free cash flow stands at $118.43M, reached in 2021; the historical low of −$56.65M was recorded in 2022.
Ovid Therapeutics Free Cash Flow by Year
Ovid Therapeutics Free Cash Flow 2025: −$38.33M
2025's free cash flow for Ovid Therapeutics came in at −$38.33M, plunged 31.6% below 2024.
Ovid Therapeutics Free Cash Flow 2024: −$56.03M
Ovid Therapeutics posted free cash flow of −$56.03M in 2024, grew 22.0% from 2023.
Ovid Therapeutics Free Cash Flow 2023: −$45.92M
In 2023, Ovid Therapeutics reported free cash flow of −$45.92M, declined 18.9% below 2022.
Ovid Therapeutics Free Cash Flow 2022: −$56.65M
Ovid Therapeutics free cash flow in 2022 was −$56.65M, plunged 147.8% below 2021. This figure represents the lowest annual value in the available history.
Ovid Therapeutics Free Cash Flow 2021: $118.43M
Ovid Therapeutics free cash flow in 2021 was $118.43M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Free Cash Flow
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $11.77B | |
| $8.97B | |
| $8.10B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $11.77B
- $8.97B
- $8.10B
- $4.52B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation